WAT — Waters Corporation
Is WAT overbought or oversold? Here is the current MarketMoodz read.
Waters Corporation (WAT) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $425.32. The rating moved from Overbought to Neutral on October 2, 2026.
- Public ratingNeutral (as of October 3, 2026)
- Last close$425.32
- Last changeMoved from Overbought to Neutral on October 2, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
AI analysis
Waters Corporation is a leading supplier of chromatographic and mass spectrometry systems with a durable installed base that drives recurring consumables and service revenue. Financially the company exhibits solid margins and cash flow, supporting capital allocation and commercial investments. Near-term performance is sensitive to pharma/diagnostics capital spending and broader market risk aversion; however, continued investor appetite for select late‑stage biologics and specialty biotech can provide steady demand for analytical instrumentation. Recent insider filings and a resilient aftermarket business are constructive, while macro uncertainty, IPO cooling in the device/healthtech space, payer pricing pressure and supply chain risks represent the main near‑term downside scenarios. Over the next month, catalysts to monitor include quarterly results, order momentum from biopharma customers, and any shifts in macro funding conditions that affect R&D and capital budgets.
Key factors
- Market leadership in liquid chromatography and mass spectrometry instruments with strong installed base generating recurring consumables and service revenue
- Exposure to biopharma R&D and late‑stage biologics demand, which supports instrument replacement and capital spending over cycle
- High gross margins and consistent cash generation supporting R&D, buybacks and steady operating performance
- Recent insider Form 4 activity (positive/neutral filings) suggests management/institutional alignment with equity value
- Aftermarket services and consumables provide revenue resilience versus cyclic instrument sales
- Earnings season and continued conviction flows into select specialty biotech could create read-through demand for analytical instruments
Risks
- Macro-driven risk-off environment and reduced capex at pharma/diagnostics customers could delay instrument purchases and depress near-term revenue
- Cooling IPO window and lower deal activity in device/digital-health segments may reduce short‑term demand from startup/scale‑up labs
- Policy and payer pressures (e.g., Medicare negotiations) that compress pharma margins could lead to tighter R&D budgets over time
- Supply chain disruption or component shortages that raise costs or delay shipments
- Currency volatility and geographic exposure could weigh on reported results and margins
- Intensifying competition from other instrument vendors and potential technology substitution risk over multi-year horizon
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for WAT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.